BioMedNewsBreaks

TuesdaySep 05, 2023 12:00 pm

BioMedNewsBreaks – Longeveron Inc. (NASDAQ: LGVN) to Present at Upcoming H.C. Wainwright Global Investment Conference

Longeveron (NASDAQ: LGVN, LGVNR), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-related Frailty, today announced that its management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference. The event is slated to take place in New York City from Sept. 11-13, 2023. Longeveron’s CEO Wa’el Hashad will give a pre-recorded presentation highlighting the company’s cellular therapy programs, which will be available on-demand by clicking here for the duration of the conference. The company’s CFO Lisa Locklear will also attend the…

Continue Reading

TuesdaySep 05, 2023 11:47 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, will be presenting at the 25th annual H.C. Wainwright Global Investment Conference. The conference is slated for Sept. 11–13, 2023, in New York City. According to the announcement, CNS Pharmaceuticals CEO Climaco is scheduled to present during the two-day conference; his live webcast presentation is scheduled for Wednesday, Sept. 13, at 10:30 a.m. ET. In addition to the presentation, key CNPS officials will be available to participate in in-person and virtual one-on-one meetings with…

Continue Reading

FridaySep 01, 2023 2:50 pm

BioMedNewsBreaks — BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Positioned Favorably with Worldwide License to Anti-IL-17 NanoAbs

BiondVax (NASDAQ: BVXV), a biotechnology company that recently signed an exclusive worldwide license to develop and commercialize innovative alpaca-derived nanosized antibodies (“NanoAbs”) targeting IL-17 cytokines as treatments for psoriasis and psoriatic arthritis, recently received coverage in analysis by Aegis Capital Corp. The report, which reiterated a buy recommendation and $70 target price for BVXV, contained analysis highlighting a deal valued at approximately $2.4 billion for Eli Lilly and Company’s (NYSE: LLY) acquisition of DICE Therapeutics Inc. (NASDAQ: DICE), a biopharmaceutical company that develops oral therapeutic candidates – such as DC-806 and DC-853, both oral interleukin-17 (“IL-17”) inhibitors – currently in…

Continue Reading

FridaySep 01, 2023 12:17 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Patent Protection in ‘Some of the Most Important Markets in the World’

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, recently received a patent from the China National Intellectual Property Administration. “The granted patent broadly covers the use of the company’s drug candidate REQORSA(R) immunogene therapy in combination with PD-1 antibodies, such as Keytruda(R), to treat cancers. The REQORSA gene therapy in combination with Keytruda is the subject of the company’s ongoing Acclaim-2 clinical trial for the treatment of non-small cell lung cancer (‘NSCLC’). In this trial, the company is enrolling and treating patients with advanced, metastatic NSCLC whose disease progressed…

Continue Reading

WednesdayAug 30, 2023 11:08 am

BioMedNewsBreaks — Renovaro BioSciences Inc. (NASDAQ: RENB) Congratulates GEDiCube on New Joint Effort Clinical Trials

Renovaro BioSciences Inc. (NASDAQ: RENB) (formerly NASDAQ: ENOB), an advanced, preclinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy, released a statement congratulating GEDiCube on its joint effort to accelerate early diagnosis of cancer in clinical trials. GEDiCube is partnering with NVIDIA Inception on clinical trials focused on advancing a unique platform for early cancer detection. The platform combines techniques for boosting the body’s natural tumor-fighting mechanisms with artificial intelligence and machine learning technology. “This is a natural fit for GEDiCube that will help us in our mission to detect cancer at its earliest stage,” said GEDiCube…

Continue Reading

WednesdayAug 30, 2023 10:16 am

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Participation at Upcoming National Investment Banking Association Conference

Longeveron (NASDAQ: LGVN; LGVNR), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and aging-related frailty, will be presenting at the 149th annual Conference of the National Investment Banking Association. The annual conference is slated for Sept. 6–7, 2023, in Fort Lauderdale, Florida. According to the announcement, Longeveron CEO Wa’el Hashad will be providing an overview of the company, along with its cellular therapy programs. The company noted that its executive management team will also be at the presentation to discuss clinical trial progress and investment…

Continue Reading

FridayAug 25, 2023 2:14 pm

BioMedNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Is Fast on the Trail to Target IL-17

BiondVax (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, in-licensed the next antibody from the Max Planck Institute – a NanoAb designed to target interleukin-17 (“IL-17”) for the treatment of psoriasis, HS and other important indications. “BiondVax is now fast on the trail of developing what could be a very promising drug. Autoimmune diseases are often chronic and require patients to take drugs for life, with annual sales for current anti-interleukin-17 monoclonal antibodies totaling about $7.5 billion. With their NanoAbs, BiondVax aims to generate a…

Continue Reading

ThursdayAug 24, 2023 1:04 pm

BioMedNewsBreaks – SOHM, Inc. (SHMN) Announces Strategic Board Appointment of Dr. Krishna Bhat, MD, Ph.D., FACC

SOHM (OTC: SHMN), a pharmaceutical, nutraceutical and cosmeceutical company that manufactures and markets generic drugs covering numerous treatment categories, today announced the appointment of Dr. Krishna Bhat, MD, Ph.D., FACC, an experienced bioscientist and cardiologist, to serve on its advisory board as a chief medical advisor. According to the update, Dr. Bhat has a practice of over 35 years in the field of clinical and interventional cardiology. He is also a recipient of the 2021 Hall of Fame Award from the American Heart Association and the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute,…

Continue Reading

ThursdayAug 24, 2023 10:53 am

BioMedNewsBreaks – RVL Pharmaceuticals plc (NASDAQ: RVLP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference

RVL Pharmaceuticals (NASDAQ: RVLP), a specialty pharmaceutical company focused on the commercialization of UPNEEQ(R) (oxymetazoline hydrochloride ophthalmic solution) (“UPNEEQ”), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, will be represented at the 25th annual H.C. Wainwright Global Investment Conference. The company announced that CEO Brian Markson will be participating in a fireside chat during the event, which is scheduled for Sept. 12, 2023. Markison will also be hosting one-on-one investor meetings during the conference, which will be held in New York City. Markison’s fireside chat is slated to begin at 11:30 a.m. ET. and can be…

Continue Reading

WednesdayAug 23, 2023 1:13 pm

BioMedNewsBreaks – Renovaro BioSciences Inc. (NASDAQ: RENB) Eyes Clear Path to IND Submission for Innovative Cancer Platform

Renovaro BioSciences (NASDAQ: RENB), (formerly NASDAQ: ENOB), announced that it remains confident in submitting an Investigational New Drug Application (“IND”) for its innovative Cancer Platform in early/mid 2024 following review of comments made by the U.S. Food and Drug Administration (“FDA”) on the company’s Pre-IND submission. The company’s proprietary, novel technology uses cell- and gene-therapy to promote renewed immune response against solid tumors. “We are grateful to the FDA for the very timely, thorough and clear direction that was provided. After a comprehensive review by our management, scientific, regulatory, and clinical operations teams, we believe we have a clear path…

Continue Reading